164 related articles for article (PubMed ID: 26050156)
1. Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.
Binkhorst L; Kloth JSL; de Wit AS; de Bruijn P; Lam MH; Chaves I; Burger H; van Alphen RJ; Hamberg P; van Schaik RHN; Jager A; Koch BCP; Wiemer EAC; van Gelder T; van der Horst GTJ; Mathijssen RHJ
Breast Cancer Res Treat; 2015 Jul; 152(1):119-128. PubMed ID: 26050156
[TBL] [Abstract][Full Text] [Related]
2. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
de Graan AJ; Teunissen SF; de Vos FY; Loos WJ; van Schaik RH; de Jongh FE; de Vos AI; van Alphen RJ; van der Holt B; Verweij J; Seynaeve C; Beijnen JH; Mathijssen RH
J Clin Oncol; 2011 Aug; 29(24):3240-6. PubMed ID: 21768449
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial.
Neven P; Jongen L; Lintermans A; Van Asten K; Blomme C; Lambrechts D; Poppe A; Wildiers H; Dieudonné AS; Brouckaert O; Decloedt J; Berteloot P; Verhoeven D; Joerger M; Vuylsteke P; Wynendaele W; Casteels M; Van Huffel S; Lybaert W; Van Ginderachter J; Paridaens R; Vergote I; Dezentjé VO; Van Calster B; Guchelaar HJ
Clin Cancer Res; 2018 May; 24(10):2312-2318. PubMed ID: 29459457
[No Abstract] [Full Text] [Related]
4. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Kloth JS; Binkhorst L; de Wit AS; de Bruijn P; Hamberg P; Lam MH; Burger H; Chaves I; Wiemer EA; van der Horst GT; Mathijssen RH
Clin Pharmacokinet; 2015 Aug; 54(8):851-8. PubMed ID: 25647628
[TBL] [Abstract][Full Text] [Related]
5. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
6. Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.
Jager NG; Linn SC; Schellens JH; Beijnen JH
Clin Breast Cancer; 2015 Aug; 15(4):241-4. PubMed ID: 25997856
[TBL] [Abstract][Full Text] [Related]
7. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2007 Apr; 21(2):191-7. PubMed ID: 17391292
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
[TBL] [Abstract][Full Text] [Related]
9. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
10. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
12. An UPLC-MS/MS method for separation and accurate quantification of tamoxifen and its metabolites isomers.
Arellano C; Allal B; Goubaa A; Roché H; Chatelut E
J Pharm Biomed Anal; 2014 Nov; 100():254-261. PubMed ID: 25173109
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.
Ruddy KJ; Desantis SD; Gelman RS; Wu AH; Punglia RS; Mayer EL; Tolaney SM; Winer EP; Partridge AH; Burstein HJ
Breast Cancer Res Treat; 2013 Oct; 141(3):421-7. PubMed ID: 24062210
[TBL] [Abstract][Full Text] [Related]
14. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.
de Vries Schultink AH; Zwart W; Linn SC; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2015 Aug; 54(8):797-810. PubMed ID: 25940823
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
Zembutsu H
Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women.
Fuchs WS; Leary WP; van der Meer MJ; Gay S; Witschital K; von Nieciecki A
Arzneimittelforschung; 1996 Apr; 46(4):418-22. PubMed ID: 8740091
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Dowsett M; Cuzick J; Howell A; Jackson I;
Br J Cancer; 2001 Aug; 85(3):317-24. PubMed ID: 11487258
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats.
Piao Y; Shin SC; Choi JS
Biopharm Drug Dispos; 2008 May; 29(4):245-9. PubMed ID: 18338336
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 pharmacogenomics of tamoxifen treatment.
Technol Eval Cent Assess Program Exec Summ; 2008 May; 23(1):1-4. PubMed ID: 18663817
[No Abstract] [Full Text] [Related]
[Next] [New Search]
